Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma
This Viewpoint presents 4 arguments against routinely substituting zoledronic acid with denosumab in patients with newly diagnosed multiple myeloma.
Related Articles
Identifying and Measuring Administrative Harms
This qualitative study using a mixed-methods approach examines the identification of and proposed measures to address administrative harms.
Securement to Prevent Noncuffed Central Venous Catheter Dislodgement in Pediatrics
This superiority randomized clinical trial compares the rates of dislodgement for noncuffed central venous catheters secured with a subcutaneous anchor securement system with sutureless securement…
Disparities in Medication Use for Criminal Justice System–Referred Opioid Use Disorder Treatment
This cross-sectional study analyzes the disparity in the use of medications for opioid use disorder between individuals referred to treatment by the criminal justice system…
Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome
This prespecified analysis of the POST-PCI randomized clinical trial analyzes clinical outcomes in patients with vs without acute coronary syndrome (ACS) who have undergone high-risk…
Hospital Capacity Data and Extreme Heat Event Vulnerability
This qualitative study examines how regional health care capacity is associated with extreme heat event vulnerability.
Intensive Blood Pressure Control in Adults Aged 75 Years or Older
This randomized clinical trial evaluates the effects of intensive (<120 mm Hg) systolic blood pressure targets compared with standard (<140 mm Hg) systolic blood pressure…
Neighborhood Child Opportunity and Preterm Birth Rates by Race and Ethnicity
This cross-sectional study of infants born in Massachusetts examines whether a multidimensional measure of neighborhood child opportunity is associated with preterm birth.
Persons With Cancer Rather Than Cancer Patients—Semantics Matter
This essay describes a physician’s shift to patient-focused language in treatment of patients with cancer.
Medical Aid in Dying
This Viewpoint discusses aspects of medical aid in dying laws in the US, including patient access, clinician authorization, and waiting periods.
Cancer Trial Eligibility and Therapy for Duffy Null–Associated Neutrophil Count
This cross-sectional study assesses whether phase 3 cancer clinical trials and systemic anticancer therapy regimens continue to exclude or recommend dose modifications for absolute neutrophil…